Fred Hutchinson Cancer Research Center is the third institution to gain an academic bridge program in collaboration with Evotec, with the latest instalment dubbed Lab591.
Fred Hutchinson Cancer Research Center became the third institution today to form a partnership with drug discovery company Evotec by launching Lab591.
The program is also being supported by investment firm Arix Biosciences. Lab591 will work towards accelerating the commercialisation of cancer and infectious disease drugs.
Evotec will work with faculty to conduct initial research that will be seed funded by Arix. If the project proves successful, Evotec and Arix will launch a spinout.
Lab591 has been named in honour…
